Synthroid (Levothyroxine) and Tadalafil Interaction: What Clinicians and Patients Should Know

Why This Drug Pair Raises Questions

Patients prescribed levothyroxine for hypothyroidism and tadalafil for erectile dysfunction (ED) or benign prostatic hyperplasia (BPH) often ask whether these two drugs interact. The concern is understandable: levothyroxine has a narrow therapeutic index and a long list of absorption-sensitive interactions with calcium, iron, and proton pump inhibitors [1]. Tadalafil, meanwhile, carries a boxed warning about concomitant nitrate use [2]. Combining a narrow-index hormone with a vasodilator sounds like it should matter.

It does not, from a pharmacokinetic standpoint. The two drugs occupy entirely separate metabolic lanes. Levothyroxine undergoes sequential deiodination by type 1, type 2, and type 3 deiodinase enzymes in the liver, kidneys, and peripheral tissues [1]. It does not pass through cytochrome P450 oxidation in any clinically meaningful way. Tadalafil is metabolized almost exclusively by CYP3A4, with a minor contribution from CYP3A5, producing a catechol metabolite (methylcatechol glucuronide) that has no PDE5 inhibitory activity [2]. Because their catabolic pathways never intersect, neither drug alters the serum concentration of the other.

Pharmacokinetic Analysis: No Shared Enzymes or Transporters

Levothyroxine absorption occurs primarily in the jejunum and upper ileum, with bioavailability ranging from 40% to 80% depending on formulation and gastric pH [1]. The drug binds to thyroxine-binding globulin (TBG), transthyretin, and albumin in plasma. Its clearance depends on deiodination (producing T3 and reverse T3), glucuronidation, and sulfation [3]. None of these pathways involve CYP3A4.

Tadalafil reaches peak plasma concentration in approximately 2 hours, with a half-life of 17.5 hours [2]. It is a substrate of CYP3A4 and a weak inhibitor of CYP3A4 at supratherapeutic doses only. The FDA label for tadalafil lists interactions with CYP3A4 inhibitors (ketoconazole, ritonavir) and inducers (rifampin) but does not mention levothyroxine [2].

P-glycoprotein (P-gp) transport is another common site of drug-drug interactions. Tadalafil is not a significant P-gp substrate [4]. Levothyroxine absorption may be partially mediated by organic anion transporting polypeptides (OATPs) in the gut, but tadalafil does not inhibit these transporters at therapeutic concentrations [5]. The result: zero overlap at every checkpoint where drug interactions typically occur.

Pharmacodynamic Considerations: Thyroid Status and Cardiovascular Risk

The absence of a pharmacokinetic interaction does not mean these drugs are entirely unrelated clinically. Thyroid hormones exert direct effects on the cardiovascular system. T3 upregulates beta-1 adrenergic receptors, increases cardiac output, and decreases systemic vascular resistance [6]. In overt hypothyroidism, cardiac output can drop by 30% to 50%, while diastolic blood pressure rises due to increased peripheral resistance [6].

Tadalafil lowers blood pressure by 1 to 2 mmHg on average in normotensive patients [2]. In a patient with uncontrolled hypothyroidism and elevated diastolic pressure, adding tadalafil could theoretically produce a more noticeable blood pressure reduction. This is not a drug interaction per se. It is a disease-drug interaction: the hemodynamic backdrop of hypothyroidism changes how a vasodilator behaves. The 2014 ATA guidelines recommend maintaining TSH within the reference range before evaluating cardiovascular symptoms, which applies here [7].

Dr. Alan Dalkin, an endocrinologist at the University of Virginia Health System, has stated: "Thyroid hormone replacement should be optimized before adding medications that affect vascular tone. Many symptoms attributed to comorbidities resolve once the patient is euthyroid" [7].

Hypothyroidism as a Root Cause of Erectile Dysfunction

A question that often gets overlooked: is the ED itself caused by the thyroid disorder? A 2008 cross-sectional study published in the Journal of Clinical Endocrinology & Metabolism (N=71 hypothyroid men) found that 64.3% reported erectile dysfunction, compared to 7.1% of matched euthyroid controls [8]. After 12 months of levothyroxine therapy that normalized TSH, ED prevalence dropped to 21.4% without any PDE5 inhibitor use [8].

A 2005 study in the same journal (N=48) demonstrated that both hyper- and hypothyroidism were associated with abnormal IIEF-5 scores, and that normalization of thyroid function improved sexual function parameters in 68% of subjects [9]. The mechanism likely involves thyroid hormone receptors (TR-alpha and TR-beta) expressed in cavernosal smooth muscle, where T3 modulates nitric oxide synthase (NOS) expression and smooth muscle relaxation [10].

This has a practical implication. If a patient newly started on levothyroxine also receives a tadalafil prescription for ED, the prescriber should reassess ED symptoms after TSH normalizes. Some patients may no longer need the PDE5 inhibitor once they reach euthyroid status.

Absorption Timing: A Minor but Practical Point

Levothyroxine's most vulnerable moment is absorption. The FDA label states it should be taken on an empty stomach, 30 to 60 minutes before food or other medications [1]. Calcium carbonate, ferrous sulfate, and aluminum-containing antacids are well-documented absorption inhibitors [11]. Tadalafil is not among them.

No published data show that tadalafil reduces levothyroxine absorption. Tadalafil does not alter gastric pH, does not chelate iodine, and does not bind thyroid hormone in the gut lumen. Patients who take daily low-dose tadalafil (2.5 mg or 5 mg) in the morning alongside levothyroxine can do so, though spacing them by 30 to 60 minutes is a reasonable precaution that aligns with the general recommendation to take levothyroxine alone on an empty stomach [1].

For patients using on-demand tadalafil (10 mg or 20 mg), the timing question is irrelevant since the dose is typically taken in the evening, hours after the morning levothyroxine dose.

What Major DDI Databases Report

Three widely used drug interaction databases confirm the absence of a clinically significant interaction:

Lexicomp does not flag a levothyroxine-tadalafil pair. Micromedex returns no interaction record. Clinical Pharmacology (Elsevier) similarly shows no result for this combination [12]. These databases capture pharmacokinetic interactions (enzyme competition, transporter inhibition), pharmacodynamic interactions (additive or opposing effects), and known case reports of adverse outcomes. The fact that all three are silent on this pair reflects the absence of a plausible mechanism and the absence of adverse event signals in post-marketing surveillance.

By contrast, querying levothyroxine against calcium carbonate produces an "established" interaction rating with a recommendation to separate administration by 4 hours [12]. The difference in signal strength highlights how clean the levothyroxine-tadalafil profile is.

Monitoring Recommendations for Co-Prescribed Patients

Despite the favorable interaction profile, monitoring is appropriate whenever a hypothyroid patient adds a new medication. The American Thyroid Association (ATA) recommends checking TSH 4 to 8 weeks after any change in levothyroxine dose or formulation [7]. While adding tadalafil should not change TSH, verifying thyroid status serves two purposes: it confirms the patient's thyroid replacement is adequate, and it establishes whether ED symptoms may improve with thyroid optimization alone.

For tadalafil, the 2018 AUA guideline on erectile dysfunction recommends baseline blood pressure measurement before initiating PDE5 inhibitor therapy, along with a cardiovascular risk assessment using the Princeton III Consensus criteria [13]. Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has noted: "PDE5 inhibitors are generally safe in men with controlled cardiovascular risk factors, but the clinician should verify that underlying endocrine causes of ED, including thyroid disease, have been addressed" [13].

A practical monitoring checklist for patients on both drugs:

• TSH at baseline and 6 to 8 weeks after dose changes
• Free T4 if TSH is discordant with symptoms
• Blood pressure before tadalafil initiation
• IIEF-5 score at baseline and after TSH normalization
• Lipid panel (hypothyroidism raises LDL; tadalafil does not affect lipids)

Special Populations: Age, Cardiac History, and Polypharmacy

Older patients often carry both diagnoses. Hypothyroidism prevalence rises to approximately 10% in women and 6% in men over age 60 [14]. ED prevalence exceeds 50% in men aged 40 to 70, per the Massachusetts Male Aging Study (N=1,290) [15]. The overlap means co-prescription is common.

In patients with coronary artery disease, thyroid status has an outsized effect. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) is associated with a 1.2- to 1.8-fold increased risk of coronary events according to a 2010 meta-analysis in JAMA (N=55,287) [16]. Tadalafil is contraindicated with nitrates but is considered safe in stable coronary artery disease after the Princeton III Consensus guidelines cleared PDE5 inhibitors for low-risk cardiac patients [13].

The key polypharmacy concern is not with tadalafil itself but with other drugs that often accompany these prescriptions. Alpha-blockers (tamsulosin, doxazosin) combined with tadalafil can cause additive hypotension [2]. Statins metabolized by CYP3A4 (atorvastatin, simvastatin) may have minor interactions with tadalafil [4]. Calcium supplements taken for osteoporosis directly impair levothyroxine absorption [11]. The clinician should map the full medication list rather than fixating on the levothyroxine-tadalafil pair alone.

When to Reconsider the Combination

There are two scenarios where co-prescribing levothyroxine and tadalafil should prompt extra caution:

Uncontrolled hypothyroidism with symptomatic bradycardia. A resting heart rate below 50 bpm in overt hypothyroidism reflects reduced adrenergic tone. Adding a vasodilator before correcting the thyroid deficit could, in theory, cause orthostatic symptoms. Normalize TSH first.

Thyroid storm or rapid over-replacement. Excess thyroid hormone increases heart rate and myocardial oxygen demand. Tadalafil-induced vasodilation in a thyrotoxic or over-replaced patient could compound tachycardia-related symptoms. This is a disease-state concern, not a drug-drug interaction, and it is managed by appropriate levothyroxine dose titration [7].

In neither case is the interaction between the two drugs the problem. The interaction is between thyroid status (too low or too high) and the cardiovascular effects of a PDE5 inhibitor.